A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county

Rotaru,Maria; Jitian,Cristina  Raluca; Iancu,Gabriela  Mariana

doi:10.3892/ol.2019.10098

A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county

Authors:
- Maria Rotaru
- Cristina Raluca Jitian
- Gabriela Mariana Iancu
View Affiliations

Affiliations: Department of Dermatology, Faculty of Medicine, ‘Lucian Blaga’ University of Sibiu, 550245 Sibiu, Romania, Clinic of Dermatology, Clinical Hospital of Sibiu, 550245 Sibiu, Romania
Published online on: March 1, 2019 https://doi.org/10.3892/ol.2019.10098
Pages: 4145-4148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is considered to be the most aggressive skin cancer, with an increasing incidence worldwide. An accurate staging of melanoma is crucial in describing the cancer status, estimating prognosis and deciding the optimal treatment solution. In the present study, melanoma staging highlights the importance of early detection, most of the patients having been diagnosed with advanced stages of this skin cancer. A retrospective study was conducted among 117 patients of the Academic Emergency County Hospital of Sibiu, diagnosed with melanoma between 2007 and 2016. The staging of the patients with melanoma was made using the American Joint Committee on Cancer (AJCC) 7th edition, and reconsidered in the light of the AJCC 8th edition. The results showed that the majority of the cases had distant metastases, 40.17% were diagnosed with stage IV melanoma. 25.65% of the patients were diagnosed with stage III melanoma, having a regional disease. The rest of the cases had localized melanoma (stages I and II, 30.76%), while only 3.42% of them were diagnosed with melanoma in situ, the melanoma type with the greatest chances of survival. Analyzing the Breslow index, it was observed that the most common tumor thickness was 2.1 to 4 mm (34.19%). In conclusion, as the incidence of melanoma increases in Romania, further efforts are needed to improve the early detection of melanoma. There are hopes that with the correct and early diagnosis of melanoma, the mortality rate of this neoplasm will decrease in the future.

View Figures

View References

1	Neagu M, Caruntu C, Constantin C, Boda D, Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin carcinogenesis: Updates in experimental models (Review). Oncol Rep. 35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
2	Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M and Fitzmaurice C: The global burden of melanoma: Results from the Global Burden of Disease Study 2015. Br J Dermatol. 177:134–140. 2017. View Article : Google Scholar : PubMed/NCBI
3	Forsea AM, Del Marmol V, de Vries E, Bailey EE and Geller AC: Melanoma incidence and mortality in Europe: New estimates, persistent disparities. Br J Dermatol. 167:1124–1130. 2012. View Article : Google Scholar : PubMed/NCBI
4	Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Safaei Diba C, Eser S, Gavric Z, Primic-Zakelj M, et al: Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer. 55:47–55. 2016.PubMed/NCBI
5	European Cancer Information System: Measuring cancer burden and its time trends across. https://ecis.jrc.ec.europa.eu
6	Rockberg J, Amelio JM, Taylor A, Jörgensen L, Ragnhammar P and Hansson J: Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence. Int J Cancer. 139:2722–2729. 2016. View Article : Google Scholar : PubMed/NCBI
7	Forsea AM, Del Marmol V, Stratigos A and Geller AC: Melanoma prognosis in Europe: Far from equal. Br J Dermatol. 171:179–182. 2014. View Article : Google Scholar : PubMed/NCBI
8	Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, Lopez MC, Innos K, Minicozzi P, Borgognoni L, et al EUROCARE-5 Working Group, : Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. Eur J Cancer. 51:2179–2190. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
10	Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endo. 10:545–558. 2014. View Article : Google Scholar
11	Boda D: Cellomics as integrative omics for cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
12	Rotaru M, Nati AE, Avrămoiu I, Grosu F and Mălăescu GD: Digital dermoscopic follow-up of 1544 melanocytic nevi. Rom J Morphol Embryol. 56:1467–1472. 2015.PubMed/NCBI
13	Watson M, Geller AC, Tucker MA, Guy GP Jr and Weinstock MA: Melanoma burden and recent trends among non-Hispanic whites aged 15–49 years, United States. Prev Med. 91:294–298. 2016. View Article : Google Scholar : PubMed/NCBI
14	Tripp MK, Watson M, Balk SJ, Swetter SM and Gershenwald JE: State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 66:460–480. 2016. View Article : Google Scholar
15	McMasters KM, Sondak VK, Lotze MT and Ross MI: Recent advances in melanoma staging and therapy. Ann Surg Oncol. 6:467–475. 1999. View Article : Google Scholar : PubMed/NCBI
16	Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
17	Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al: Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI
18	Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, et al: Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med. 6:2203–2212. 2017. View Article : Google Scholar : PubMed/NCBI
19	Populaţia României pe localităţi (după domiciliu), . Institutul Naţional de Statistică România. http://www.insse.ro/cms/sites/default/files/field/publicatii/populatia_romaniei_dupa domiciliu_la_1_iul_2016_0.pdfJuly 1–2016
20	Youlden DR, Baade PD, Soyer HP, Youl PH, Kimlin MG, Aitken JF, Green AC and Khosrotehrani K: Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: A Population-Based Study. J Invest Dermatol. 136:2270–2276. 2016. View Article : Google Scholar : PubMed/NCBI
21	Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, Chirlaque MD, Coza D, Galceran J, Gavin A, et al: Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer. 92:108–118. 2018. View Article : Google Scholar : PubMed/NCBI
22	Tsoutsos D, Papadopoulos S, Kehagias G, Mara A, Kyriopoulou E, Karonidis A, Spiliopoulos K, Mpalitsaris E, Karapiperis G, Panayotou P, et al: Epidemiological trends in the diagnosis of melanoma in a Southern European population: Analysis of a large database from a tertiary referral center. Melanoma Res. 28:348–358. 2018.PubMed/NCBI
23	Astrua C, Fava P, Brizio M and Savoia P: A study of melanoma in Eastern European migrants in Italy. Eur J Dermatol. 27:139–143. 2017.PubMed/NCBI
24	van der Leest RJ, Zoutendijk J, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E and Hollestein LM: Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations? Eur J Cancer. 51:2833–2841. 2015. View Article : Google Scholar : PubMed/NCBI
25	Helvind NM, Hölmich LR, Smith S, Glud M, Andersen KK, Dalton SO and Drzewiecki KT: Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: A National Database Study of 24,059 melanoma cases. JAMA Dermatol. 151:1087–1095. 2015. View Article : Google Scholar : PubMed/NCBI
26	Andersson TM, Eriksson H, Hansson J, Månsson-Brahme E, Dickman PW, Eloranta S, Lambe M and Lambert PC: Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. Cancer Epidemiol. 38:93–99. 2014. View Article : Google Scholar : PubMed/NCBI
27	Eriksson H, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, Naredi P, Stierner U, Carstensen J and Hansson J: Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: A nationwide population-based study from Sweden. J Clin Oncol. 32:1356–1364. 2014. View Article : Google Scholar : PubMed/NCBI